Regimen | Grade | Present study | Phase 3 trials |
---|
CapeOX | All Grade | 54.4 % | 78.0 %a
|
≥ Grade 3 | 1.80 % | 11.0 %a
|
mFOLFOX6 | All Grade | 90.0 % | 92.0 %b
|
≥ Grade 3 | 40.0 % | 12.5 %b
|
- Grade of neuropathy was evaluated according to the Common Terminology Criteria for Adverse Events version 3.0.
-
aData from reference [8]; bResult of FOLFOX4 [9]. Effectiveness and safety of mFOLFOX6 were comparable to those of FOLFOX4 [10].